Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.125.041925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Giselle Alexandra Suero-Abreu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cardio-Oncology Program, Division of Cardiology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Plaque, Atherosclerotic, Neoplasms, Atherosclerosis. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) are associated with a 3‐fold risk of atherosclerotic cardiovascular disease (ASCVD). However, the biology of atherosclerosis is different among women and men, and ASCVD risk factors among women treated with an ICI are incompletely understood. This study aimed to identify factors associated with ASCVD in women following ICIs and to characterize plaque progression.
Methods
In a single‐center retrospective study, clinical and cancer‐related factors were compared among women treated with ICIs who did and did not experience ASCVD. Competing risk analysis estimated the effect of ICIs on cardiovascular risk. In an imaging substudy, the rate of atherosclerotic plaque progression post‐treatment was compared between women and men.
Results
Among 1188 female patients treated with an ICI, 54 (5%) experienced an ASCVD with a median time to event of 174 days. Patients with ASCVD had a higher prevalence of prior myocardial infarction and coronary revascularization (15% versus 6%, P =0.007) and prior stroke (7% versus 2%, P =0.039). Competing risk analyses, adjusting for cardiovascular risk factors, revealed an almost 3‐fold increased risk of post‐ICI ASCVD in women with prior cardiovascular events (hazard ratio, 2.71 [95% CI, 1.24–5.95]; P =0.013). In an imaging study, the annual rate of plaque progression post‐ICI was 6% for total and 7% for non‐calcified plaque, with similar rates of progression observed in women and men.
Conclusions
In female patients treated with ICIs, 5% developed an ASCVD, and a history of cardiovascular events was a risk factor. In an imaging study, plaque progressed in a short time frame after ICI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardio-Oncology Program, Division of Cardiology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.
- Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology Massachusetts General Hospital, Harvard Medical School Boston MA USA.
- Heart and Vascular Center Semmelweis University Budapest Hungary.
- Department of Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany.
- MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Center for Pharmacology and Drug Research & Development, Department of Pharmacology and Pharmacotherapy Semmelweis University Budapest Hungary.
- Division of Oncology and Hematology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.
ORCID-Profile: Giselle Alexandra Suero-Abreu, Carlos A Gongora, Jana Taron, Julia Karady, Bela Merkely, Zoltan V Varga, Ryan J Sullivan, Kerry L Reynolds, Daniel Zlotoff, Borek Foldyna, Markella V Zanni, Tomas G Neilan
Förderung
- NIDDK NIH HHS
Zitieren
APA
Suero-Abreu, G. A., Drobni, Z. D., Gongora, C. A., Taron, J., Karady, J., Gilman, H. K., Merkely, B., Vago, H., Varga, Z. V., Sullivan, R. J., Reynolds, K. L., Zlotoff, D., Foldyna, B., Zanni, M. V., & Neilan, T. G. (2025). Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041925
Vancouver
Suero-Abreu GA, Drobni ZD, Gongora CA, Taron J, Karady J, Gilman HK, et al. Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.041925
BibTeX
@article{SueroAbreu2025,
author = {Suero-Abreu, Giselle Alexandra and Drobni, Zsofia D and Gongora, Carlos A and Taron, Jana and Karady, Julia and Gilman, Hannah K and Merkely, Bela and Vago, Hajnalka and Varga, Zoltan V and Sullivan, Ryan J and Reynolds, Kerry L and Zlotoff, Daniel and Foldyna, Borek and Zanni, Markella V and Neilan, Tomas G},
title = {Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.125.041925}
}
EUVIMED